Assessment of the clinical activity of Nivolumab in patients with advanced Hereditary Leiomyomatosis and Renal Cell Carcinoma-associated kidney cancer as salvage therapy following treatment with antiangiogenic targeted therapy
Latest Information Update: 27 Oct 2021
At a glance
- Drugs Nivolumab (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 27 Oct 2021 New trial record
- 13 Sep 2021 Results presented at the 116th Annual Meeting of the American Urological Association